The application of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) cannot completely reverse podocyte injury or glomerulosclerosis 4,5, suggesting that other mechanisms are involved in Ang II-induced podocyte injury. Here, AGT is linked to glomerulosclerosis.